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SURGICAL	MENOPAUSE	AND	FRAILTY	RISK	
IN	COMMUNITY-DWELLING	OLDER	WOMEN:	
THE	STUDY	OF	OSTEOPOROTIC	FRACTURES	
GRACE	HUANG	
ABSTRACT	
Background:		Low	testosterone	levels	in	older	women	have	been	shown	to	be	
associated	frailty.	Whether	older	postmenopausal	women	with	a	history	of	bilateral	
oophorectomy	before	natural	menopause	resulting	in	lower	testosterone	levels	(surgical	
menopause)	have	higher	risk	for	frailty	is	not	known.	This	prospective	study	investigated	
whether	women	who	had	surgically-induced	menopause	had	a	greater	risk	of	frailty	
than	naturally	menopausal	women.	Furthermore,	we	also	determined	whether	lower	
serum	testosterone	levels	would	be	associated	with	frailty	in	our	study	population	of	
older	postmenopausal	women.				
	
Methods:	The	sample	included	7699	community-dwelling	white	women	aged	≥	65	years	
from	the	Study	of	Osteoporotic	Fractures	(SOF).	Participants	were	determined	to	have	
undergone	surgical	versus	natural	menopause	based	on	whether	or	not	they	reported	
retrospectively	having	undergone	a	bilateral	oophorectomy	before	or	after	menopause.		
Frailty	status	was	classified	as	not	frail,	somewhat	frail	(hereafter	referred	to	as	
Intermediate	stage),	frail	or	death	at	four	interviews,	conducted	6–18	years	post-
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baseline.	Baseline	serum	total	testosterone	concentrations	were	available	on	a	subset	of	
541	participants.	
	
Results:	Approximately	12.6%	of	the	participants	reported	surgical	menopause.	A	total	
of	39.7%	were	classified	as	somewhat	frail	(intermediate	stage)	and	10.1%	as	frail.	
Twenty-two	(22.0%)	of	the	participants	died	during	the	interview	period	when	frailty	
was	assessed.	Mean	age	at	baseline	was	71.2	years.		Total	serum	testosterone	levels	
were	significantly	lower	among	surgically	menopausal	women	compared	to	naturally	
menopausal	women	(p<0.01).	Surgical	menopause	was	not	significantly	associated	with	
an	increased	risk	of	frailty	(Odds	Ratio=0.94;	95%	CI=0.72–1.22),	intermediate	stage	
frailty	(Odds	Ratio=0.96;	95%	CI=0.80–1.10)	or	death	(Odds	Ratio=1.17	;	95%	CI=0.97–
1.42)	after	adjusting	for	age,	BMI	and	number	of	IADL	impairments.	Stratified	analyses	
showed	that	oral	estrogen	use	did	not	modify	these	associations.		
	
Conclusion:	Among	postmenopausal	women,	surgical	menopause	was	not	associated	
with	a	higher	risk	for	frailty	compared	to	naturally	menopausal	women,	even	in	the	
absence	of	estrogen	therapy.	Future	prospective	studies	are	needed	to	investigate	
hormonal	mechanisms	involved	in	the	development	of	frailty	in	older	postmenopausal	
women.
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BACKGROUND	
	
	
Significance	of	Frailty	in	Older	Postmenopausal	Women	
	
Frailty	has	become	an	increasingly	important	concept	among	clinicians	as	a	complex	
biological	syndrome	in	older	individuals	of	increased	vulnerability	to	stressors.	Frailty	
results	from	age-related	declines	in	physical	function	and	physiologic	reserves	[1,	2].	As	
a	result,	frail	individuals	are	at	increased	risk	for	disease	and	premature	death	[3].	Frailty	
has	been	consistently	associated	with	higher	rates	of	disability,	morbidity	and	mortality	
[4].	Approximately	10.7%	of	community	dwelling	older	individuals	are	frail	and	
prevalence	has	been	reported	to	be	higher	in	women	(9.2–10%)	than	in	men	(4.9–5.5%)	
[5].		The	frailty	phenotype	was	originally	defined	as	having	3	or	more	of	the	following	
criteria:	unintentional	weight	loss,	self-reported	exhaustion,	weak	grip	strength,	slow	
walking	speed	and	low	physical	activity	[2];	however,	other	modified	definitions	have	
been	used	[6].	The	pathophysiology	of	frailty	is	not	well	understood	but	is	thought	to	
result	from	age-related	dysregulation	of	multiple	physiologic	systems	including	
inflammation,	sarcopenia,	nutrition	and	hormonal	dysfunction	[7–10].	Specifically,	
hormonal	changes	during	menopause	have	been	associated	with	decline	in	physical	
functioning	and	theorized	to	contribute	to	aging	and	frailty	in	older	women	[11].	
Furthermore,	approximately	1	in	9	women	age	35–45	years	has	undergone	
hysterectomy,	with	40%	undergoing	concurrent	bilateral	oophorectomy	[12,	13],	
resulting	in	abrupt	onset	of	menopause	and	decline	in	both	serum	testosterone	and	
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estradiol	levels.		Although	several	studies	have	suggested	an	association	of	surgical	
menopause	(premenopausal	bilateral	oophorectomy)	with	increased	risk	of	
cardiovascular	disease,	physical	dysfunction,	osteoporosis	and	mortality	[14];	no	
prospective	cohort	study	has	assessed	the	impact	of	surgical	menopause	on	long-term	
risk	for	frailty.		Understanding	how	surgical	menopause	(a	form	of	early	menopause)	
contributes	to	the	frailty	syndrome	is	important	in	helping	us	target	treatment	and	
prevention	strategies	for	better	health	outcomes	as	these	women	enter	into	older	age.			
	
Relationship	of	Menopause	with	Frailty	
Age-related	declines	in	sex	steroids	may	be	an	important	factor	in	the	
pathophysiology	of	frailty	in	older	women.	Lower	serum	testosterone	levels	in	men	have	
been	shown	in	several	studies	to	predict	frailty	in	older	men	[15–17].	On	the	contrary,	
studies	examining	the	association	between	sex	hormones	and	frailty	in	women	are	
scarce.	Women	experience	age-related	decline	in	hormones,	particularly	during	the	time	
of	menopause.	During	natural	menopause,	the	most	significant	change	occurs	with	the	
sudden	and	permanent	cessation	of	ovarian	follicle	formation	and	decline	in	estrogen	
production.	In	women,	the	menopausal	transition	has	been	associated	with	an	
accelerated	loss	of	muscle	mass	and	strength	and	subsequent	decrease	in	physical	
function	[18,	19],	which	in	turn	may	increase	risk	for	the	development	of	frailty.		Data	
from	the	Study	of	Women’s	Health	Across	the	Nation	(SWAN)	study	have	also	
demonstrated	association	of	the	menopausal	transition	with	decline	in	grip	strength,	an	
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important	predictor	of	frailty	status	[19].	The	decline	in	estrogen	associated	with	
menopause	has	long	been	suspected	to	be	the	cause	of	multiple	aspects	of	poor	health	
in	women,	including	loss	of	muscle	mass	and	strength,	which	are	core	features	of	the	
frailty	syndrome.	However,	evidence	is	limited	on	whether	this	loss	of	estrogen	
significantly	affects	muscle	mass	and	physical	function	as	clinical	trials	of	estrogen	
replacement	in	improving	these	measures	in	women	have	yielded	conflicting	results	
[20–22].			
	
Relationship	of	Menopause	and	Testosterone	Levels	with	Frailty	
Because	of	the	adverse	sequelae	related	to	sarcopenia,	tremendous	research	has	
focused	more	recently	on	anabolic	hormones	(Testosterone,	Insulin-like	growth	factor	1,	
dehydroepiandrosterone	sulfate)	and	their	relationship	to	physical	health	outcomes	and	
frailty.	Specifically,	emerging	evidence	suggests	that	testosterone	may	play	an	important	
role	in	muscle	performance	and	overall	physical	health	in	postmenopausal	women.		
Serum	testosterone	levels	are	lower	in	older	postmenopausal	women	than	in	young	
menstruating	women;	however,	unlike	estrogen,	the	decline	does	not	change	abruptly	
during	natural	menopause	and	becomes	a	major	source	of	androgens	contributing	to	
approximately	50%	of	the	total	testosterone	production	[23].	In	contrast	to	natural	
menopause,	surgical	menopause	(premenopausal	bilateral	oophorectomy)	does	result	
in	significant	decline	in	testosterone	levels	[24].	Testosterone	levels	are	known	to	
decline	progressively	with	age	in	women;	and	very	low	testosterone	levels	in	older	
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women	are	associated	with	a	higher	prevalence	of	frailty	[25].	Thus,	women	who	have	
undergone	surgical	menopause	may	be	at	increased	risk	for	frailty	as	bilateral	
oophorectomy	is	known	to	result	in	dramatic	decline	in	testosterone	levels	[26].			
	
Relationship	Between	Surgical	Menopause	and	Physical	Health	Outcomes	
In	observational	studies,	surgically	menopausal	women	report	higher	rates	of	
physical	limitation	when	compared	to	naturally	menopausal	women	[11,	27].	In	a	large	
population-based	longitudinal	study	of	midlife	women,	women	with	surgical	menopause	
(with	or	without	estrogen)	were	found	to	have	significantly	reduced	levels	of	several	
objective	measures	of	physical	function	(2-pound	lift,	stair	climb,	timed	walk,	sit-to-
stand)	in	addition	to	self-perceived	decrease	in	physical	functioning	compared	to	
naturally	menopausal	women	[11].	Since	lower	testosterone	levels	are	associated	with	
frailty	in	older	women	[28],	surgically	menopausal	women	may	be	a	population	at	risk.	
Evidence	from	these	epidemiological	studies	raises	the	possibility	that	ovarian	
hormones	may	have	a	significant	role	in	protection	from	physical	disability	and	frailty.		
Hence,	surgically	menopausal	women	enter	into	a	state	of	anabolic	hormone	deficiency	
(i.e.	low	testosterone)	and	may	be	at	increased	risk	for	physical	limitations	and	frailty	as	
they	enter	into	older	age.	Thus,	low	testosterone	levels	may	be	a	key	regulator	of	the	
frailty	process	in	these	women.	To	our	knowledge,	no	prospective	study	to	date	has	
compared	the	risk	for	developing	frailty	in	surgically	menopausal	versus	naturally	
menopausal	women.	Although	previous	studies	have	found	that	menopause	is	
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associated	with	specific	components	of	the	frailty	syndrome	[19,	29],	these	studies	did	
not	differentiate	between	natural	versus	surgical	menopause.		
	
Aim	of	Current	Study	
Utilizing	data	from	participants	in	the	Study	of	Osteoporotic	Fractures	(SOF),	we	
aimed	to	test	the	hypothesis	that	women	who	have	undergone	surgical	menopause,	
which	results	in	lower	testosterone	levels,	would	be	at	higher	risk	for	developing	frailty	
compared	to	women	who	went	through	menopause	naturally;	and	that	this	risk	would	
be	attenuated	with	estrogen	therapy.	Furthermore,	we	hypothesized	that	lower	serum	
testosterone	levels	would	be	associated	with	frailty.				
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METHODS	
Study	Sample	
The	sample	for	the	current	study	was	a	subsample	of	participants	enrolled	in	the	
Study	of	Osteoporotic	Fractures	(SOF).	SOF	is	a	multicenter,	prospective	cohort	study	of	
9704	older	community-dwelling	white	women	≥	65	years	of	age	recruited	from	1986–
1988	that	was	designed	to	study	risk	factors	for	osteoporosis,	falls	and	fractures.		
Women	who	had	previous	history	of	fracture,	undergone	bilateral	hip	replacement	or	
who	were	unable	to	walk	without	assistance	were	excluded.	Participants	were	recruited	
from	four	U.S	geographical	areas:	Baltimore,	MD,	Minneapolis,	MN,	the	Monongahela	
Valley,	PA	and	Portland,	OR.			Interviews	and	comprehensive	clinical	assessments	were	
conducted	approximately	every	two	years	since	1986	(Baseline	visit	through	Visit	9,	
conducted	between	1986	and	2008).			A	total	of	9314	women	at	baseline,	self-reported	
their	age	at	menopause,	whether	they	had	one	or	both	of	their	ovaries	removed	and	if	
so,	at	what	age.		Of	these	9314	women,	7699	had	data	on	frailty	status	and	death	
assessed	at	the	4th	(conducted	between	1992	and	1994),	5th	(1995–1996),	6th	(1997–
1998)	and	8th	(2004–2005)	SOF	visits.	A	total	of	1012	of	the	9314	women	died	before	
the	1st	frailty	assessment.	Thus,	we	used	18	years	of	prospectively	collected	incident	
frailty	data	from	SOF.	The	present	analysis	was	restricted	to	7699	women	with	available	
data	on	menopause	history,	frailty	status	and	death	during	these	18-years	of	follow-up.				
(See	Figure	1)	
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Type	of	Menopause	
At	baseline,	reproductive	history	by	interviewer-administered	questionnaire	was	
obtained	including	history	and	age	of	hysterectomy	and/or	oophorectomy	(unilateral	or	
bilateral)	and	age	at	menopause	(defined	as	“age	of	last	menstrual	period”	+	1	year	for	
naturally	menopausal	women	or	age	when	bilateral	oophorectomy	was	performed	for	
surgically	menopausal	women).		A	participant	was	considered	to	have	had	surgical	
menopause	if	she	had	both	ovaries	removed	prior	to	menopause.	Participants	who	had	
at	least	one	ovary	after	her	reported	age	at	menopause	were	classified	as	having	natural	
menopause,	which	was	the	reference	group	for	our	analyses.	We	also	conducted	
secondary	analyses	defining	natural	menopause	as	women	who	underwent	natural	
menopause	without	previous	hysterectomy	or	oophorectomy	in	case	there	was	
misclassification	bias	with	respect	to	their	date	and	type	of	surgery.			
	
Frailty		
	 Frailty	status	was	formally	categorized	at	SOF	visits	4,	5,	and	6	which	correspond	
to	6,	8	and	10	years	of	follow-up	from	baseline,	respectively.	We	also	used	data	from	
Visit	8	(18-years	of	follow-up)	on	the	components	specified	to	categorize	frailty	status	as	
our	measure	of	incident	frailty.	Frailty	was	defined	based	on	the	established	SOF	
criteria,	which	is	a	variation	on	the	Fried	criteria	[2].		The	SOF	criteria	consisted	of	three	
components:	(1)	intentional	or	unintentional	weight	loss	>5lbs	in	the	past	year,	(2)	
inability	to	rise	from	a	chair	five	consecutive	times	without	using	the	arms,	and	(3)	
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perceived	reduced	energy	level,	based	on	an	item	from	the	Geriatric	Depression	Scale	
[6].	Participants	who	had	at	least	two	out	of	three	criteria	were	categorized	as	“frail”;	
whereas	1	out	of	three	was	considered	“intermediate”	stage	and	participants	who	met	
no	criteria	were	defined	as	“not	frail”.		A	participant	was	considered	an	incident	case	of	
frailty	at	the	first	follow-up	visit	where	she	met	criteria	for	frailty.		For	example,	if	a	
participant	was	classified	at	Visit	4	as	“not	frail”	and	reassessed	as	“frail”	at	Visit	5,	she	
was	classified	as	“frail”	in	the	analysis.		A	participant	who	was	“not	frail”	at	Visit	4	and	
either	terminated	from	the	study	before	a	subsequent	visit,	or	was	not	re-assessed	for	
frailty	was	classified	as	“not	frail”	in	the	analysis	(similar	for	all	other	follow-up	visits).	A	
participant	who	was	either	“not	frail”	or	“somewhat	frail”	at	Visit	4	and	died	before	a	
subsequent	visit	was	classified	as	“died”	in	the	analysis	(similar	for	all	other	follow-up	
visits).	The	number	of	incident	frail	cases	observed	over	the	follow-up	period	was	149,	
137,	152	and	339	at	Visits	4,	5,	6,	and	8,	respectively.	Thus,	a	total	of	777	women	
became	frail	over	the	follow-up	period;	3054	became	Intermediate	stage	and	2176	who	
were	assessed	in	at	least	one	or	more	of	these	visits	were	not	frail	cases	across	all	visits	
in	our	analytic	sample.	In	addition,	a	total	of	1692	women	were	classified	as	death	cases	
between	Visit	4	and	Visit	8.	The	main	analyses	assessed	the	association	of	menopause	
status	with	all	levels	of	the	frailty	outcome	(not	frail,	Intermediate,	or	frail)	and	death.		
	
Covariables	
	 Data	on	age,	years	of	education,	smoking	status,	body	mass	index	(BMI),	number	
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of	instrumental	activities	of	daily	living	(IADL)	the	participant	had	difficulty	performing,	
walking	speed,	oral	corticosteroid	use,	oral	estrogen	use,	total	number	of	years	on	oral	
estrogen,	chronic	diseases	and	self-rated	health	were	collected	at	baseline	(Visit	1).	Oral	
corticosteroid	and	oral	estrogen	use	were	categorized	as	never,	past	and	current	use.	
The	number	of	chronic	diseases	was	tabulated	as	a	count	of	the	following	four	diseases:	
coronary	heart	disease,	diabetes	mellitus,	stroke	and	chronic	obstructive	pulmonary	
disease	(COPD).	Walking	speed	was	measured	as	the	time	in	seconds	it	took	for	a	
participant	to	walk	at	usual	pace	over	a	6-meter	course	[30]	
	
Blood	Collection	and	Hormone	measurements	
	 Blood	was	collected	at	baseline	examination	from	all	participants	from	1986	to	
1988	after	an	overnight	fast	and	was	immediately	frozen	to	-20°C.	Within	2	weeks,	all	
samples	were	shipped	to	a	central	repository	and	stored	in	liquid	nitrogen	at	-190°C	
until	hormones	were	assayed.	Testosterone	assays	were	available	only	on	a	small	subset	
of	women	(n=541)	included	in	the	breast	cancer	and	fracture	substudies	of	SOF.	
Methodology	of	testosterone	measurements	was	similar	for	total	testosterone	but	not	
free	testosterone	between	the	two	substudies.	Therefore,	only	total	testosterone	was	
analyzed	given	consistency	in	assay	measurement	in	this	small	subset	of	women.	Serum	
concentrations	of	total	testosterone	(ng/dl)	were	measured	by	radioimmunoassay	after	
extraction	and	aluminum	oxide	column	chromatography	with	interassay	coefficient	of	
variation	of	6.1–13.4%	[31,	32].		
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Statistical	analysis	
Characteristics	of	women	who	underwent	surgical	versus	natural	menopause	
were	compared	using	student	t-test	for	continuous	variables	and	Chi-square	tests	for	
categorical	variables.	Multinomial	logistic	regression	was	used	to	assess	the	association	
of	menopause	status	with	all	levels	of	the	frailty	outcome	(not	frail,	intermediate	or	
frail)	and	death	in	a	single	model.	Important	known	clinical	correlates	of	frailty	were	
determined	a	priori	to	be	included	in	the	multivariable	model.		
Covariates	that	were	examined	as	potential	confounders	included	the	number	of	
chronic	diseases	(count	of	the	following	diseases:	coronary	heart	disease,	diabetes	
mellitus,	stroke,	COPD),	never/past/current	oral	estrogen	use,	never/past/current	oral	
corticosteroid	use,	walking	speed	(m/s)	and	number	of	impairments	in	instrumental	
activities	of	daily	living	(IADL).	Covariables	that	were	significantly	associated	with	both	
type	of	menopause	and	frailty	were	retained	as	covariates	in	the	model	(p	≤	0.05	for	
model	entry).	Age	at	baseline	and	Body	Mass	Index	(BMI)	were	considered	clinically	
important	covariates	that	were	forced	into	the	multivariate	model	[5,	33].	We	also	
performed	stratification	analysis	investigating	the	association	of	type	of	menopause	and	
frailty	among	never,	past	and	current	oral	estrogen	users.	All	statistical	analyses	were	
performed	using	SAS,	version	9.1.	
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RESULTS	
Sample	Characteristics	
	 Details	of	the	SOF	study	participants	included	in	our	analysis	are	provided	in	
Figure	1.	Of	the	9704	Caucasian	participants	in	the	original	SOF	cohort,	9314	had	
available	data	on	menopause	type.	Of	these	9314	women,	1012	died	before	Visit	4	(1st	
frailty	assessment)	and	603	had	missing	data	on	frailty	status.		A	total	of	1692	women	
died	during	the	time	period	of	frailty	outcome	assessments	between	Visit	4	and	Visit	8	
(18-years	of	follow-up	from	baseline	visit).	Therefore,	a	total	of	7699	postmenopausal	
women	with	available	data	on	menopause	type,	frailty	status	and	death	during	the	18-
years	of	follow-up	were	included	in	our	analytic	sample.	Mean	age	and	BMI	were	71.2	±	
5.2	years	and	26.4	±	4.4	kg/m2,	respectively.		13.8%	were	current	oral	estrogen	users	
while	27.6%	used	oral	estrogen	in	the	past.	Surgically	menopausal	participants	
represented	12.6%	of	the	analytic	sample.	
The	baseline	characteristics	of	our	study	sample	are	shown	in	Table	1.	Compared	
to	naturally	menopausal	women,	surgically	menopausal	women	went	through	
menopause	at	a	significantly	younger	age,	had	a	longer	time	period	since	menopause,	
higher	frequency	of	past	and/or	current	oral	estrogen	use	and	longer	time	period	of	oral	
estrogen	use	(11.7	years	vs.	7.7	years).	Surgically	menopausal	women	also	had	
significantly	lower	serum	total	testosterone	levels	compared	to	naturally	menopausal	
women	(13.2	±	8.2	vs.	21.7	±	14.9	ng/dl;	p<0.0001).	However,	surgically	and	naturally	
menopausal	participants	did	not	significantly	differ	in	age,	years	of	education,	smoking	
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status,	BMI,	oral	steroid	use	and	walking	speed.	Nor	were	there	differences	in	the	
percentage	of	women	who	reported	poor	health	status	or	number	of	chronic	medical	
conditions.			
Association	between	Surgical	Menopause	and	Risk	of	Frailty	
Overall	average	age	at	frailty	in	our	study	was	79.6	years.	In	terms	of	frailty	
status,	3054	subjects	(39.7%)	were	categorized	as	being	intermediate	stage	and	777	
subjects	(10.1	%)	as	being	frail	in	our	sample.		Using	multinomial	logistic	regression,	we	
found	no	significant	association	between	type	of	menopause	(surgical	versus	natural	
menopause)	with	all	levels	of	the	frailty	outcome	(not	frail,	intermediate	stage	or	frail)	
including	death.	(Frailty:	Odds	Ratio=0.94;	95%	CI=0.72–1.22;	Intermediate	Stage:	Odds	
Ratio=	Odds	Ratio=0.96;	95%	CI=0.80–1.10;	Death:	Odds	Ratio=1.17;	95%	CI=0.97–1.42)	
(Table	2)	after	adjusting	for	age,	BMI	and	number	of	IADL	impairments.	The	results	were	
non-significant	in	setting	of	low	prevalence	of	frail	cases	(10.1%).		
	
Stratified	Analyses	by	Oral	Estrogen	Use	
To	assess	whether	estrogen	played	a	role	in	the	association	between	surgical	
menopause	and	frailty	status	or	death,	stratified	analyses	between	never,	past	or	
current	oral	estrogen	users	was	performed	using	multinomial	logistic	regression	and	
shown	in	Tables	3a,	3b	and	3c.		There	was	no	significant	effect	modification	by	oral	
estrogen	use	across	all	levels	of	frailty	including	death.			
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Association	of	Serum	Total	Testosterone	and	Frailty	
	 Using	multinomial	logistic	regression	in	a	subset	of	541	participants,	we	found	no	
significant	association	between	baseline	serum	total	testosterone	levels	with	all	levels	of	
the	frailty	outcome	including	death	in	the	overall	study	population.	(Table	4).		Due	to	
small	sample	size,	we	did	not	have	adequate	power	to	assess	for	effect	modification	
among	surgically	versus	naturally	menopausal	women.	
	
Sensitivity	Analyses	
When	redefining	natural	menopause	as	women	with	both	intact	uterus	and	ovaries,	
women	who	had	undergone	surgical	menopause	did	not	have	significantly	higher	risk	
for	frailty	or	death	compared	to	naturally	menopausal	women.	(Table	5)		Subsequent	
analyses	excluding	women	older	than	85	years	also	did	not	significantly	alter	the	results.	
Adjustments	for	age	at	menopause	also	did	affect	the	results.	(data	not	shown)		
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DISCUSSION	
In	a	large	sample	of	older	Caucasian	women,	we	found	that	women	with	
surgically-induced	menopause	were	not	at	increased	risk	for	developing	frailty	in	
comparison	to	naturally	menopausal	women.	Contrary	to	our	hypothesis,	our	findings	
suggest	that	low	serum	testosterone	levels	may	not	be	a	primary	mechanism	to	explain	
higher	rates	of	frailty	in	older	postmenopausal	women.	Furthermore,	estrogen	use	did	
not	significantly	alter	this	relationship.	This	is	the	first	population-based	cohort	study	
investigating	the	association	between	surgically-induced	menopause	and	frailty	risk	
among	postmenopausal	women.		These	results	advance	the	knowledge	about	age-
related	decline	in	testosterone	concentrations	and	frailty	in	postmenopausal	women,	
which	has	previously	been	confined	to	studies	in	men	[15,	17].	
In	our	study,	women	who	had	previously	undergone	bilateral	oophorectomy	had	
significantly	lower	serum	testosterone	levels	and	subsequently	were	hypothesized	to	be	
at	increased	risk	for	developing	frailty.	This	is	in	contrast	to	natural	menopause,	where	
the	ovary	continues	to	secrete	a	substantial	amount	of	androgens	[34]	so	that	
circulating	testosterone	levels	change	very	little	during	the	perimenopausal	period.		
However,	the	surgically	menopausal	women	in	our	cohort	did	not	have	higher	risk	for	
frailty	compared	to	naturally	menopausal	women	over	18-years	of	follow-up.	Androgens	
play	an	important	role	in	the	maintenance	of	muscle	mass,	bone	health	and	physical	
function	[35,	36].	Although	frailty	has	not	been	previously	assessed	in	surgically	
menopausal	women,	one	clinical	trial	demonstrated	that	testosterone	replacement	
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therapy	in	oophorectomized	women	resulted	in	significant	increases	in	total	lean	body	
mass	[37].	Although	the	ovaries	are	an	important	source	of	testosterone	in	women,	our	
results	do	not	support	use	of	testosterone	therapy	to	prevent	sarcopenia	and	physical	
impairments	associated	with	frailty	in	surgically	menopausal	women.	Future	prospective	
studies	are	needed	to	validate	our	findings.		
In	addition	to	low	testosterone,	other	biological	mechanisms	possibly	involved	
may	include	the	mediating	effects	of	estrogen	on	frailty.	Estrogen	decline	during	natural	
menopause	has	been	associated	with	an	accelerated	loss	of	muscle	mass	and	strength	
and	subsequent	decrease	in	physical	function	[18,	19],	suggesting	a	beneficial	role	for	
estrogen	replacement.	In	contrast	to	naturally	menopause,	surgically	menopausal	
women	in	our	study	had	higher	rates	of	current	and	past	estrogen	use.	However,	frailty	
risk	was	not	altered	whether	or	not	women	used	estrogen	in	our	study.		Our	results	
contradict	those	of	a	recent	study	that	found	that	higher	endogenous	estradiol	levels	
were	associated	with	frailty	in	older	women	who	had	undergone	natural	menopause	
[38].	Although	the	women	in	this	study	were	not	surgically	menopausal,	these	results	
shed	light	into	the	uncertainty	of	whether	estrogen	has	beneficial	versus	harmful	effects	
in	postmenopausal	women.	It	also	important	to	note	that	these	women	were	enrolled	
in	the	late	1980s	during	a	time	when	the	safety	concerns	over	hormone	replacement	
therapy	brought	out	by	the	Women’s	Health	Initiative	were	not	prominent,	making	our	
study	population	not	representative	of	the	estrogen	prescribing	practices	today.	
In	the	context	of	other	physical	health	outcomes	related	to	frailty,	our	results	are	
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similar	to	findings	in	other	studies	evaluating	association	of	surgical	oophorectomy	and	
osteoporotic	fractures.	Previous	analyses	of	the	SOF	cohort	showed	that	older	
postmenopausal	women	with	history	of	bilateral	oophorectomy	before	natural	
menopause	were	not	at	increased	risk	for	nonvertebral	fractures	over	21	years	of	
follow-up	[12].	Similar	findings	on	fracture	risk	were	also	found	in	women	who	had	
undergone	postmenopausal	bilateral	oophorectomy	[39].	The	similar	negative	findings	
between	these	results	and	our	study	occurred	despite	the	fact	we	had	surgically	
menopausal	women	who	were	younger	at	oophorectomy	(average	age	44)	versus	the	
other	study	conducted	in	postmenopausal	oophorectomized	women	(average	age	49).	
In	contrast	to	postmenopausal	bilateral	oophorectomy,	surgical	menopause	is	by	
definition	bilateral	oophorectomy	prior	to	natural	menopause;	based	on	our	data,	it	
appears	that	experiencing	more	time	in	menopause	(i.e.	longer	exposure	time	to	low	
testosterone	levels)	does	not	confer	higher	risk	for	negative	physical	health	outcomes	
associated	with	frailty	which	is	reassuring.	
Our	study	had	notable	strengths.	This	was	a	large	sample	size	cohort	
representing	older	ambulatory	women	of	diverse	geographical	areas	in	the	U.S.	No	
study	to	date	has	investigated	the	association	between	surgical	menopause	and	frailty	
risk	in	older	women.	As	many	previous	studies	on	frailty	in	women	were	of	cross-
sectional	design,	SOF	was	a	prospective	longitudinal	study	where	the	participants	were	
followed	through	frequent	biennial	assessments	over	the	course	of	18	years.	
Additionally,	we	used	a	multinomial	modeling	to	capture	all	levels	of	the	frailty	
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syndrome	as	well	as	the	competing	risk	of	death	in	our	study	population.	The	SOF	
criteria	for	the	frailty	syndrome	used	in	this	study	was	a	simpler	and	well-validated	
modification	of	the	more	complex	Fried	criteria,	which	may	potentially	be	more	
practical	for	clinical	settings	[6].		
Our	study	also	had	some	limitations.	The	SOF	sample	was	comprised	of	primarily	
white	women,	aged	65	and	older	without	significant	physical	impairments	at	
enrollment.	Thus,	our	results	are	not	representative	of	other	races	and	high-risk	
populations	for	disability.	While	we	can	assume	that	menopause	preceded	frailty	in	our	
sample,	we	lacked	medical	records	to	confirm	type	of	surgery	and	age	at	oophorectomy.	
Misclassification	of	surgical	menopause,	although	possible,	would	have	been	very	
unlikely	to	occur	because	this	group	demonstrated	the	significantly	lower	serum	
testosterone	concentrations	that	would	be	expected	in	comparison	to	natural	
menopause.	Given	that	misclassification	of	natural	menopause	could	have	also	
occurred,	sensitivity	analyses	restricting	the	natural	menopause	group	to	women	with	
both	intact	ovaries	and	uterus	was	conducted	and	did	not	alter	the	results.	The	sample	
size	of	our	frailty	cases	represented	only	10%	of	our	population	and	was	possibly	too	
small	of	a	proportion	to	detect	significant	differences.	Because	the	age	at	menopause	
occurred	over	a	very	wide	range	(18–59	years)	and	frailty	was	only	assessed	at	4	time	
points	over	18-years	of	follow-up,	there	may	not	have	been	sufficient	time	for	many	
subjects	to	develop	frailty,	which	is	a	more	slowly	progressive	chronic	condition.	In	
addition,	frailty	was	not	assessed	in	a	large	number	of	participants	given	that	they	had	
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died	during	the	frailty	outcome	assessment	period.	Thus,	the	relatively	low	percentage	
of	prevalent	frailty	cases	and	competing	risk	of	death	may	explain	the	null	findings	
observed	in	our	study.	Although	the	frailty	syndrome	is	on	a	continuum,	it	is	unclear	
whether	surgically	menopausal	women	in	our	study	could	have	progressed	to	frailty	
with	time.	As	this	is	a	retrospective	cohort	study	design,	the	covariates	used	in	our	
multivariate	analysis	such	as	BMI	and	IADL	impairments	were	all	measured	at	
enrollment	into	the	study	(age>65),	long	after	the	time	of	baseline	exposure	(i.e.	surgical	
vs.	natural	menopause),	making	it	possible	for	these	variables	to	be	on	the	causal	
pathway	rather	than	confounders.	In	addition,	hormone	measurements	(total	
testosterone)	were	only	measured	at	a	single	time	point	and	in	small	subset	of	
participants,	which	may	not	be	representative	of	individual	and	diurnal	variations	that	
are	commonly	seen.	Additionally,	total	testosterone	was	measured	by	a	less	sensitive	
radioimmunoassay	and	not	by	gold	standard	technique	of	tandem	mass	spectrometry	
(LC-MS/MS)	[40].	
In	conclusion,	our	study	demonstrates	that	surgically-induced	menopause	is	not	
associated	with	increased	risk	for	frailty.	Furthermore,	serum	total	testosterone	
concentrations	were	also	not	significantly	associated	with	frailty	in	both	surgically	and	
naturally	menopausal	women.	These	findings	provide	some	reassurance	that	long-term	
risk	of	frailty	is	not	significantly	increased	in	women	who	experienced	surgical	
menopause,	regardless	if	they	were	taking	estrogen	therapy.	Our	results	were	limited	in	
the	setting	of	small	sample	size,	low	prevalence	of	frailty	cases	and	competing	risk	of	
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death.	Despite	our	negative	findings,	questions	still	remain	regarding	the	benefits	versus	
harms	of	prophylactic	oophorectomy	in	women	undergoing	hysterectomy	to	prevent	
ovarian	cancer	[41].	Thus,	the	risk	to	benefit	ratio	for	bilateral	oophorectomy	should	be	
considered	carefully	in	these	women	as	the	surgery	may	predispose	them	to	future	
disability	or	other	adverse	health	outcomes	later	in	life.	More	research	is	needed	to	
further	investigate	this	relationship	to	better	understand	the	hormonal	mechanisms	
involved	in	the	development	of	frailty	in	older	women.	
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Figure	1.	Study	Participants	in	the	Study	of	Osteoporotic	Fractures	(SOF).	7699	women	with	both	data	on	exposure		
(surgical/natural	menopause)	and	outcome	(frailty	status	or	death)	constituted	the	analytical	sample	
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Table	1.	Baseline	Characteristics	of	7699	SOF	Participants	
Characteristics	
	
Natural	
Menopause	
(n=6731)	
Surgical	
Menopause	
(n=968)	
P-value	
	
Age	(yr)			 71.3	(5.0)	 70.6	(4.7)	 <0.01	
Smoking	Status	(n/%)	
				Nonsmoker	
				Former	smoker	
				Current	smoker	
	
4131	(61.6)	
1962	(29.3)	
614	(9.2)	
	
575	(59.5)	
292	(30.2)	
100	(10.3)	
0.34	
Education	(yrs)		 12.8	(2.8)	 12.3	(2.7)	 <0.01	
BMI	(kg/m
2
)	 26.4	(4.4)	 26.6	(4.7)	 0.24	
Age	at	Menopause	(yr)	 48.7	(5.0)	 44.4	(7.4)	 <0.01	
Hysterectomy	(n/%)	 1946	(29.0)	 967	(99.9)	 <0.01	
Number	of	chronic	conditions	(n/%)	 0.2	(0.5)	 0.3	(0.5)	 0.01	
Number	of	IADL	impairments		 1.0	(2.1)	 1.3	(2.3)	 <0.01	
Walking	speed	(m/s)	 1.0	(0.2)	 1.0	(0.2)	 						0.51	
Oral	Corticosteroid	use	(n/%)	
				Never	
				Past		
				Current	
	
5847	(88.3)	
658	(9.9)	
120	(1.8)	
	
841	(89.7)	
91	(9.6)	
16	(1.7)	
	
0.91	
Oral	Estrogen	use	(n/%)	
			Never	
			Past	
			Current	
	
4012	(60.4)	
1840	(27.7)	
792	(11.9)	
	
350	(36.6)	
311	(32.5)	
295	(30.9)	
	
<0.01	
Total	Number	of	Years	on	Oral	Estrogen	(yrs)	 7.7	(8.6)	 11.7	(10.6)	 <0.01	
Self-rated	health	(n/%)	
					Excellent	
					Good	
					Fair/Poor/Very	Poor	
			
	
2256	(33.5)	
3497	(52.0)	
978	(14.5)	
	
272	(28.1)	
512	(52.9)	
183	(18.9)	
	
<0.01	
Total	Testosterone	(n=541)	 21.7	(14.8)	 13.2	(7.8)	 <0.01	
*Values	are	expressed	as	mean	±	sd	and/or	percentages	(%)	by	type	of	menopause.	P-
values	represent	T-tests	or	chi-square	tests	for	comparison	of	characteristics	by	
menopause	type.	Number	of	chronic	conditions	(heart	disease,	stroke,	COPD,	diabetes)		
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Table	2.	Association	Between	Type	of	Menopause	and	Incidence	of	Frailty	among	7699	SOF	Participants		
Exposure	 	 Odds	Ratios	(95%	CIs)	
Type	of	
Menopause	
n/%	Frail	 Frail	 Intermediate	 Died	
	 	 Crude	 Adjusted*	 Crude	 Adjusted*	 Crude	 Adjusted*	
Natural	 687	(10.21)	 1.00	 1.00	 1.00	 1.00	 1.00	 1.00	
Surgical	 90	(9.30)	
0.90	
(0.70–1.16)	
0.94	
(0.72–1.22)	
0.99	
(0.84–1.18)	
0.96	
(0.8–1.1)	
1.07	
(0.89–1.30)	
1.17	
(0.97–1.42)	
*adjusted	for	age,	BMI	and	number	IADL	impairments.	Naturally	menopausal	women	is	the	reference	group
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STRATIFICATION	ANALYSES	BY	ORAL	ESTROGEN	USE	
	
Table	3a.	Association	Between	Type	of	Menopause	and	Incidence	of	Frailty	among	4461	SOF	Participants	(Never	Estrogen	Users)	
Exposure	 Odds	Ratios	(95%	CIs)	
	 Frail	 Intermediate	 Died	
	 Crude	 Adjusted*	 Crude	 Adjusted*	 Crude	 Adjusted*	
Natural	 1.00	 1.00	 1.00	 1.00	 1.00	 1.00	
Surgical	 1.02	(0.69–1.51)	 0.98	(0.65–1.47)	 0.97	(0.74–1.28)	 0.97	(0.73–1.29)	 1.26	(0.94–1.70)	 1.26	(0.93–1.72)	
*adjusted	for	age,	BMI	and	number	IADL	impairments	
	
Table	3b.	Association	Between	Type	of	Menopause	and	Incidence	of	Frailty	among	2250	SOF	Participants	(Past	Estrogen	Users)	
Exposure	 Odds	Ratios	(95%	CIs)	
	 Frail	 Intermediate	 Died	
	 Crude	 Adjusted*	 Crude	 Adjusted*	 Crude	 Adjusted*	
Natural	 1.00	 1.00	 1.00	 1.00	 1.00	 1.00	
Surgical	 0.94	(0.60–1.47)	 0.95	(0.60–1.50)	 0.99	(0.75–1.31)	 1.01	(0.75–1.34)	 1.01	(0.72–1.42)	 1.06	(0.75–1.50)	
*adjusted	for	age,	BMI	and	number	IADL	impairments	
	
Table	3c.	Association	Between	Type	of	Menopause	and	Incidence	of	Frailty	among	1186	SOF	Participants	(Current	Estrogen	
Users)	
Exposure	 Odds	Ratios	(95%	CIs)	
	 Frail	 Intermediate	 Died	
	 Crude	 Adjusted*	 Crude	 Adjusted*	 Crude	 Adjusted*	
Natural	 1.00	 1.00	 1.00	 1.00	 1.00	 1.00	
Surgical	 1.05	(0.64–1.73)	 1.10	(0.66–1.85)	 1.01	(0.74–1.39)	 1.04	(0.76–1.44)	 1.18	(0.82–1.70)	 1.29	(0.89–1.88)	
*adjusted	for	age,	BMI	and	number	IADL	impairments	
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Table	4.	Association	of	Serum	Total	Testosterone	Concentrations	and	Incidence	of	Frailty	among	541	SOF	participants	
Exposure	 Odds	Ratios	(95%	CIs)	
	 Frail	 Intermediate	 Died	
	 Crude	 *Adjusted	 Crude	 *Adjusted	 Crude	 *Adjusted	
Total	Testosterone	
1.00	
(0.99–1.02)	
1.00	
(0.98–1.01)	
0.99	
(0.98–1.01)	
0.99	
(0.98–1.01)	
0.99	
(0.97–1.00)	
0.99	
(0.97–1.00)	
*adjusted	for	age,	BMI	and	number	IADL	impairments	
	
	
	
Table	5.	Association	of	Serum	Total	Testosterone	Concentrations	and	Incidence	of	Frailty	among	5480	SOF	Participants		
(Natural	menopause	defined	as	intact	bilateral	ovaries	&	uterus)	
Exposure	 Odds	Ratios	(95%	CIs)	
	 Frail	 Intermediate	 Died	
	 Crude	 Adjusted*	 Crude	 Adjusted*	 Crude	 Adjusted*	
Natural	 1.00	 1.00	 1.00	 1.00	 1.00	 1.00	
Surgical	 0.89	(0.68–1.15)	 0.97	(0.82–1.16)	 0.93	(0.79–1.11)	 0.92	(0.70–1.12)	 1.08	(0.89–1.31)	 1.16	(0.95–1.42)	
*adjusted	for	age,	BMI	and	number	IADL	impairments	
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